Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer

被引：10

作者：

Chen, Fengquan ^{[1
]}

Liu, Chunxi ^{[2
]}

Zhang, Jian ^{[3
]}

Xu, Wenfang ^{[1
]}

Zhang, Yingjie ^{[1
]}

机构：

[1] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, 44 West Culture Rd, Jinan 250012, Shandong, Peoples R China

[2] Shandong Univ, Dept Pharm, Qilu Hosp, 107 West Culture Rd, Jinan 250012, Shandong, Peoples R China

[3] Weifang Med Univ, Coll Pharm, 78166 Bao Tong West St, Weifang 261053, Shandong, Peoples R China

来源：

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2018年 / 18卷 / 09期

关键词：

Cyclin-Dependent Kinases (CDKs); palbociclib; monotherapy; combined therapy; anti-cancer; cell cycle arrest; CYCLIN-DEPENDENT KINASES; BREAST-CANCER; CELL-CYCLE; PHASE-I; SELECTIVE INHIBITOR; THERAPEUTIC TARGET; FDA APPROVAL; PD; 0332991; PD-0332991; PD0332991;

D O I：

10.2174/1871521409666170412123500

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Cyclin-Dependent Kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. These kinases are closely related to oncogenesis and have been proved to be attractive targets for designing novel anticancer agents. The CDK inhibitors can effectively suppress the excessive proliferation of tumor cells by inducing cell cycle arrest. In recent years, a large number of CDK inhibitors have entered pre-clinical and/or clinical trials. Among these compounds, the selective CDK4/6 inhibitor Palbociclib has been approved by FDA for breast cancer treatment. Moreover, Palbociclib demonstrated promising antitumor potential as monotherapy or combined therapy in numerous clinical trials. Herein, we provide a brief review focused on the recent progress of clinical studies about Palbociclib.

引用

页码：1241 / 1251

页数：11

共 63 条

[1] A theoretical study of the structure and protonation of Palbociclib (PD 0332991) [J].

Alkorta, Ibon ;

Elguero, Jose .

JOURNAL OF MOLECULAR STRUCTURE, 2014, 1056 :209-215

[2] The history and future of targeting cyclin-dependent kinases in cancer therapy [J].

Asghar, Uzma ;

Witkiewicz, Agnieszka K. ;

Turner, Nicholas C. ;

Knudsen, Erik S. .

NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (02) :130-146

[3] PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma [J].

Barton, Kelly L. ;

Misuraca, Katherine ;

Cordero, Francisco ;

Dobrikova, Elena ;

Min, Hooney D. ;

Gromeier, Matthias ;

Kirsch, David G. ;

Becher, Oren J. .

PLOS ONE, 2013, 8 (10)

[4] A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6 [J].

Baughn, Linda B. ;

Di Liberto, Maurizio ;

Wu, Kaida ;

Toogood, Peter L. ;

Louie, Tracey ;

Gottschalk, Rachel ;

Niesvizky, Ruben ;

Cho, Hearn ;

Ely, Scott ;

Moore, Malcolm A. S. ;

Chen-Kiang, Selina .

CANCER RESEARCH, 2006, 66 (15) :7661-7667

[5] FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer [J].

Beaver, Julia A. ;

Amiri-Kordestani, Laleh ;

Charlab, Rosane ;

Chen, Wei ;

Palmby, Todd ;

Tilley, Amy ;

Zirkelbach, Jeanne Fourie ;

Yu, Jingyu ;

Liu, Qi ;

Zhao, Liang ;

Crich, Joyce ;

Chen, Xiao Hong ;

Hughes, Minerva ;

Bloomquist, Erik ;

Tang, Shenghui ;

Sridhara, Rajeshwari ;

Kluetz, Paul G. ;

Kim, Geoffrey ;

Ibrahim, Amna ;

Pazdur, Richard ;

Cortazar, Patricia .

CLINICAL CANCER RESEARCH, 2015, 21 (21) :4760-4766

[6] Targeting cyclin-dependent kinases in anti-neoplastic therapy [J].

Bruyere, Celine ;

Meijer, Laurent .

CURRENT OPINION IN CELL BIOLOGY, 2013, 25 (06) :772-779

[7]

Chiron D, 2013, BLOOD, V122

[8] Discovery of [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity [J].

Chu, Xin-Jie ;

DePinto, Wanda ;

Bartkovitz, David ;

So, Sung-Sau ;

Vu, Binh T. ;

Packman, Kathryn ;

Lukacs, Christine ;

Ding, Qingjie ;

Jiang, Nan ;

Wang, Ka ;

Goelzer, Petra ;

Yin, Xuefeng ;

Smith, Melissa A. ;

Higgins, Brian X. ;

Chen, Yingsi ;

Xiang, Qing ;

Moliterni, John ;

Kaplan, Gerald ;

Graves, Bradford ;

Lovey, Allen ;

Fotouhi, Nader .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (22) :6549-6560

[9]

Clark A. S., 2014, ASCO ANN M P, V32, P527

[10] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J].

Cristofanilli, Massimo ;

Turner, Nicholas C. ;

Bondarenko, Igor ;

Ro, Jungsil ;

Im, Seock-Ah ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Loi, Sherene ;

Verma, Sunil ;

Iwata, Hiroji ;

Harbeck, Nadia ;

Zhang, Ke ;

Theall, Kathy Puyana ;

Jiang, Yuqiu ;

Bartlett, Cynthia Huang ;

Koehler, Maria ;

Slamon, Dennis .

LANCET ONCOLOGY, 2016, 17 (04) :425-439

← 1 2 3 4 5 6 7 →